SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience aims up to Rs 1,600 crore revenue in next three years

17 Dec 2025 Evaluate

Supriya Lifescience is eyeing up to Rs 1,600 crore revenue from its Lote MIDC in Ratnagiri and Ambernath facilities in the next three years. The company's Patalganga facility will take 2.5-3 years to become operational.

The company had a capex of Rs 160 crore for setting up its Ambernath facility, and Rs 350 crore for the Patalganga unit, which will be spent in a phased manner.

Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.

Supriya Lifescience Share Price

637.95 9.00 (1.43%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×